Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moclobemide, quantity: 150 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; purified talc; titanium dioxide; sodium starch glycollate; hypromellose; iron oxide yellow; lactose monohydrate; macrogol 6000; maize starch; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moclobemide, quantity: 150 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; purified talc; titanium dioxide; sodium starch glycollate; hypromellose; iron oxide yellow; lactose monohydrate; macrogol 6000; maize starch; purified water; ethylcellulose; sodium lauryl sulfate; cetyl alcohol; hydrogen peroxide; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - tolterodine tartrate, quantity: 2 mg - tablet, film coated - excipient ingredients: stearic acid; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; titanium dioxide; hypromellose; magnesium stearate - detrusitol is indicated for the treatment of patients with overactive bladder with symptoms of urinary frequency, urgency or incontinence or any combination of these symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - tolterodine tartrate, quantity: 1 mg - tablet, film coated - excipient ingredients: stearic acid; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; magnesium stearate; hypromellose; sodium starch glycollate; titanium dioxide - detrusitol is indicated for the treatment of patients with overactive bladder with symptoms of urinary frequency, urgency or incontinence or any combination of these symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - moclobemide, quantity: 300 mg - tablet, film coated - excipient ingredients: maize starch; magnesium stearate; macrogol 6000; titanium dioxide; lactose monohydrate; sodium starch glycollate; hypromellose; povidone; purified talc; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - codeine phosphate hemihydrate, quantity: 12.8 mg; ibuprofen, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; pregelatinised maize starch; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - for the temporary relief of acute moderate pain and inflammation

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fluvoxamine maleate, quantity: 100 mg - tablet, film coated - excipient ingredients: mannitol; maize starch; pregelatinised potato starch; sodium stearylfumarate; colloidal anhydrous silica; hypromellose; macrogol 6000; purified talc; titanium dioxide - movox (fluvoxamine maleate) is indicated for the treatment of major depression in adults. movox (fluvoxamine maleate) is also indicated for the treatment of obsessive compulsive disorder (ocd) in both children aged 8 years and older, adolescent, and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fluvoxamine maleate, quantity: 50 mg - tablet, film coated - excipient ingredients: mannitol; maize starch; pregelatinised potato starch; colloidal anhydrous silica; hypromellose; macrogol 6000; purified talc; titanium dioxide; sodium stearylfumarate - movox (fluvoxamine maleate) is indicated for the treatment of major depression in adults. movox (fluvoxamine maleate) is also indicated for the treatment of obsessive compulsive disorder (ocd) in both children aged 8 years and older, adolescent, and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fluvoxamine maleate, quantity: 100 mg - tablet, film coated - excipient ingredients: pregelatinised potato starch; titanium dioxide; mannitol; maize starch; macrogol 6000; sodium stearylfumarate; purified talc; hypromellose; colloidal anhydrous silica - luvox (fluvoxamine maleate) is indicated for the treatment of: major depression in adults. it is also indicated for the treatment of obsessive compulsive disorder (ocd) in children aged 8 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - fluvoxamine maleate, quantity: 50 mg - tablet, film coated - excipient ingredients: mannitol; colloidal anhydrous silica; titanium dioxide; pregelatinised potato starch; maize starch; purified talc; macrogol 6000; hypromellose; sodium stearylfumarate - luvox (fluvoxamine maleate) is indicated for the treatment of: major depression in adults. it is also indicated for the treatment of obsessive compulsive disorder (ocd) in children aged 8 years of age and older, adolescents and adults.